Info

No relapses noted

Yakoub-Agha et al.28

16 (14)a

39 months

65% at 2 years

68% at 2 years

5/16

2/14

Two relapses after allo SCT alive at 13 and 41 months after salvage chemotherapy

PFS, progression-free survival; OS, overall survival; VP, etoposide; BM, bone marrow; PB, peripheral blood; TRM, treatment-related mortality occuring in the first year after transplant; CR, complete remission; NS, not stated specifically; Dexa-BEAM, dexamethasone/BCNU/etopo-side/cytrabine/melphalan.

aTwo patients received nonmyeloablative allo SCT.

PFS, progression-free survival; OS, overall survival; VP, etoposide; BM, bone marrow; PB, peripheral blood; TRM, treatment-related mortality occuring in the first year after transplant; CR, complete remission; NS, not stated specifically; Dexa-BEAM, dexamethasone/BCNU/etopo-side/cytrabine/melphalan.

aTwo patients received nonmyeloablative allo SCT.

able 65.6 Comparative analyses detailing outcome of myeloablative transplantation for intermediate-and high-grade
0 0

Post a comment